Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors |
| |
| Authors: | C. Roux J. L. Goldstein X. Zhou A. Klemes R. Lindsay |
| |
| Affiliation: | (1) Department of Rheumatology, AP-HP Cochin Hospital, Paris Descartes University, 27 rue Faubourg Saint Jacques, Paris, 75014, France;(2) Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA;(3) Procter & Gamble, Mason, OH, USA;(4) Helen Hayes Hospital, West Havershaw, NY, USA |
| |
| Abstract: | Summary Recent evidence suggests that proton pump inhibitor (PPI) use may affect fracture risk, an important issue for patients being concurrently treated for osteoporosis. The results of our post hoc analysis showed that, regardless of PPI concomitant use, risedronate significantly reduced the risk of new vertebral fractures compared with placebo. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
